Scientists scan brains to unlock secrets of new obesity drug
NCT ID NCT05202353
Summary
This study aims to understand how a new weight-loss drug, BI 456906, affects specific receptors in the liver and pancreas compared to an approved drug, semaglutide. Researchers will use PET and MRI scans to take pictures of these receptors in 30 adults with obesity before and after 17 weeks of treatment. The goal is to gather detailed information about how these drugs work in the body, not to directly test their effectiveness for weight loss.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Amsterdam UMC, location VUMC
RECRUITINGAmsterdam, 1105 AZ, Netherlands
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.